Evidence review · standard

tirzepatide glp1 agonists

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tirzepatide-glp1-agonists`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tirzepatide-glp1-agonists

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tirzepatide-glp1-agonists/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have GLP-1 agonists (class)

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why Tirzepatide might help you

  1. You are reading about GLP-1 agonists (class) — what breaks down matters before any compound name.
  2. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.
  3. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.
  4. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

Why GLP-1 agonists (class) matters for you

  1. Drug: GLP-1 agonists (class)
  2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • Tirzepatide → metabolic load / body weight

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 14
  • Claims tagged human evidence: 0
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 14

Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.25 / 1.00 — low — animal and anecdote heavy

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration (source s1)

2025 meta-analysis of 6 RCTs (6266 subjects) showing tirzepatide (5-15mg) superior for weight loss vs placebo/GLP-1 RAs; high-certainty for ≥15% loss.

Evidence type: Published research.

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial (source s2)

2026 Lancet phase 3 trial on tirzepatide for weight maintenance in obesity.

Evidence type: Published research.

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes (source s3)

2025 mechanistic trial on tirzepatide (GLP-1/GIP agonist) effects in type 1 diabetes.

Evidence type: Published research.

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (source s4)

2025 SURMOUNT-5 trial: tirzepatide superior to semaglutide for weight loss in obesity without diabetes.

Evidence type: Published research.

Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial (source s5)

2026 phase 2 trial showing tirzepatide benefits in T1D with obesity.

Evidence type: Published research.

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis (source s6)

Systematic review and network meta-analysis of RCTs showing tirzepatide reduces MACE, CV mortality, all-cause mortality, non-fatal MI and stroke vs placebo, comparable to GLP-1RAs.

Evidence type: Published research.

Causes and consequences of discontinuation of GLP1RAs and tirzepatide (source s7)

Review on discontinuation reasons for GLP-1RAs including tirzepatide and cardiometabolic evidence.

Evidence type: Published research.

Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists (source s8)

Study finding lower retinal complication risks with tirzepatide vs other GLP-1 RAs in T2D patients.

Evidence type: Published research.

Weight Loss With GLP-1 Agonists in Nondiabetic Adults (source s9)

Analysis showing tirzepatide superior for weight loss in nondiabetic adults compared to other GLP-1 agonists.

Evidence type: Published research.

Tirzepatide for Obesity Treatment and Diabetes Prevention (source s10)

Clinical trial on long-term tirzepatide effects for obesity and preventing diabetes.

Evidence type: Published research.

Real-world use and effectiveness of tirzepatide among ... (source s11)

Real-world evidence on tirzepatide for weight loss in non-T2D patients.

Evidence type: Published research.

A real-world study of tirzepatide for weight loss in adults ... (source s12)

Observational study on tirzepatide weight loss in obese non-diabetics.

Evidence type: Published research.

Dose-Dependent Efficacy and Safety of Tirzepatide for ... (source s13)

Meta-analysis of RCTs on dose-dependent effects in non-diabetic obesity.

Evidence type: Published research.

Insights into the Mechanism of Action of Tirzepatide (source s14)

Narrative review on tirzepatide mechanisms as dual GIP/GLP-1 agonist.

Evidence type: Published research.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

GLP-1 agonists · drug map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpAOD 9604 for TirzepatideARA 290 for TirzepatideTirzepatideBPC 157 for Tirzepatide
Evidence · 14 sources · swipe →chain 8ba1f9ededee · verify chain · provenance
1 / 14
Evidence ledger 1 · tier-ranked · API
system
Combinatorial mapping (transparent): tirzepatide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence_factor(0.40); catalog.degen_score for GLP-1 agonists (class).
Model swipes · 4 from 1 model · swipe →verify
1 / 4
grok-4.3writer
draft2026-06-29 17:45
tirzepatide glp1 agonists
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tirzepatide-glp1-agonists
it output
4 source(s) added
e5e165ce2e7869e9
grok-4.3source_hunt
sources2026-06-29 17:45
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tirzepatide-glp1-agonists
it output
4 source(s) added
2abbdfb3c94910d6
grok-4.3source_hunt
sources2026-06-29 17:45
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tirzepatide-glp1-agonists
it output
4 source(s) added
478f0feeeb323592
grok-4.3source_hunt
sources2026-06-29 17:46
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tirzepatide-glp1-agonists
it output
5 source(s) added
9dd3bcbb97328c1f

Related research

GLP-1 agonists · drug map

Open evidence map →
AOD 9604 for Tirzepatideaod-9604-tirzepatideARA 290 for Tirzepatideara-290-tirzepatideTirzepatidebdnf-explained-tirzepatideBPC 157 for Tirzepatidebpc-157-tirzepatideTirzepatidecjc-1295-tirzepatideTirzepatidedihexa-tirzepatideDSIP for Tirzepatidedsip-tirzepatideTirzepatideepitalon-tirzepatideGHK Cu for Tirzepatideghk-cu-tirzepatideTirzepatideglutathione-tirzepatide
Ask this article · 3 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (system tier): "Combinatorial mapping (transparent): tirzepatide vs glp1-agonists — regen=0.38, degen=0.35, Δ=0.03. Method: layer_relevance(0.75) × evidence…"?
ask tirzepatide-glp1-agonists claim c_map_tirzepatide-glp1-agonist · paste includes §SELF
For my medical situation, what can you answer from your catalogue about tirzepatide glp1 agonists — and what would you need me to tell you first?
ask tirzepatide-glp1-agonists condition gaps · paste includes §SELF
What good and bad outcomes are documented for tirzepatide glp1 agonists (studies vs anecdotes)?
ask tirzepatide-glp1-agonists good bad experiences · paste includes §SELF
tirzepatide-glp1-agonists · posted 2026-06-29 · updated 2026-06-29 · 3 prior revisions
Ledger API & provenance
Provenance · 4 model passes · 0 tokens · $0 · 1 model
chain head febf2b2def38be94
populate-init grok-4.3 · 2026-06-29 17:45 · 0 tok · 4b1319b76ff5
sources grok-4.3 · 2026-06-29 17:45 · 0 tok · 4ec7f7717139
sources grok-4.3 · 2026-06-29 17:45 · 0 tok · 1a8da71f439e
sources grok-4.3 · 2026-06-29 17:46 · 0 tok · febf2b2def38
verify chain →
REST + ledger
read GET /api/articles/tirzepatide-glp1-agonists · GET /api/articles/tirzepatide-glp1-agonists?format=post (the editable body)
create/replace POST /api/articles/tirzepatide-glp1-agonists · PUT /api/articles/tirzepatide-glp1-agonists (replace, keeps revision) · PATCH /api/articles/tirzepatide-glp1-agonists (merge)
delete DELETE /api/articles/tirzepatide-glp1-agonists
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/tirzepatide-glp1-agonists/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/tirzepatide-glp1-agonists/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim tirzepatide-glp1-agonists|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →